2024
Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
Olszewski A, Matasar M, Huntington S, Ollila T, Pelcovits A, Tiger Y, Reagan J, Chorzalska A, Morgan J, Pardo M, McMahon J, Donnelly S, Carmody C, Margolis J, Milrod C, Dubielecka P. Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study. Blood 2024, 144: 1644. DOI: 10.1182/blood-2024-193022.Peer-Reviewed Original ResearchMarginal zone lymphomaCytokine release syndromeOverall response rateCR rateComplete responseFollicular lymphomaPartial responseOverall survivalAdverse eventsLugano criteriaImmune augmentationEfficacy analysisFirst-line treatment of FLTEMRA CD8+ T cellsCounts of NK cellsTreatment of follicular lymphomaCD8+ T cellsInterim analysisPhase 2 clinical trialCT-based criteriaCytokine release syndrome eventLow-dose lenalidomideStep-up dosingPatients discontinued treatmentPD-1 expression
2018
Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis
Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. The Oncologist 2018, 24: 955-962. PMID: 30568021, PMCID: PMC6656463, DOI: 10.1634/theoncologist.2018-0538.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMiddle AgedNivolumabPrognosisProgrammed Cell Death 1 ReceptorRetrospective StudiesSurvival RateYoung AdultConceptsProgression-free survivalClassical Hodgkin lymphomaPD-1 inhibitorsPD-1iPercent of patientsOverall response rateComplete responseResponse rateSystemic chemotherapyOverall survivalPartial responseSystemic therapyCHL patientsHodgkin's lymphomaClinical trialsRetrospective analysisToxicity profileReal-world settingDeath-1 inhibitor nivolumabMedian progression-free survivalR cHLRefractory classical Hodgkin lymphomaDeath-1 inhibitorsPrior autoimmune diseaseR cHL patients